Amlodipine Dosing for Raynaud's Phenomenon
For Raynaud's phenomenon, start amlodipine at 2.5 mg once daily and titrate cautiously to a maximum of 10 mg once daily, monitoring for hypotension and peripheral edema. 1
Dosing Algorithm
Initial Dosing
- Start low: 2.5 mg once daily 2, 3, 2
- This lower starting dose is critical in Raynaud's patients who may have baseline hypotension or be taking other vasodilators
Titration Strategy
- Increase gradually: Progress from 2.5 mg → 5 mg → 7.5 mg → 10 mg once daily
- Titration interval: Wait 7-14 days between dose increases 4
- Target dose: Up to 10 mg once daily for adequate effect 2, 3, 2
- The high doses used in pulmonary hypertension (up to 20 mg) are not appropriate for Raynaud's phenomenon
Monitoring Parameters
Dose-limiting factors that require stopping titration or reducing dose:
- Systemic hypotension (particularly problematic in Raynaud's patients with baseline low blood pressure)
- Lower limb peripheral edema 2, 3, 2
- Headache, flushing, dizziness 4
Evidence Quality and Context
The evidence for amlodipine in Raynaud's comes primarily from pulmonary hypertension guidelines 2, 3, 2 and systemic sclerosis guidelines 1, where calcium channel blockers are recommended as first-line therapy for Raynaud's phenomenon. The 2025 EULAR guidelines specifically recommend "dihydropyridine-type calcium antagonists, usually oral nifedipine" as first-line therapy 1, with amlodipine being an acceptable alternative in the same drug class.
A 2017 Cochrane review 5 found moderate-quality evidence that calcium channel blockers reduce attack frequency by approximately 2-3 attacks per week, though effects on severity and duration were modest. Importantly, amlodipine may be better tolerated than nifedipine due to its longer half-life and once-daily dosing, potentially reducing vasodilatory side effects like headache and flushing 6.
Clinical Considerations
Amlodipine advantages in Raynaud's:
- Once-daily dosing improves adherence
- Longer half-life provides more stable blood pressure control
- May cause less reflex tachycardia than nifedipine
- Suitable for patients with baseline bradycardia (unlike diltiazem) 2, 3
Common pitfalls to avoid:
- Do not start at 5 mg in Raynaud's patients—this standard hypertension dose 4 is too high initially and risks symptomatic hypotension
- Do not use immediate-release formulations—only sustained-release preparations should be used 7
- Monitor for peripheral edema, which occurs in a dose-dependent manner (1.8% at 2.5 mg, 10.8% at 10 mg) and is more common in women 4
Special populations:
- Elderly or frail patients: Start at 2.5 mg and titrate more slowly 4
- Hepatic insufficiency: Start at 2.5 mg 4
- Pediatric patients (6-17 years): Start at 2.5 mg once daily, maximum 5 mg daily 8, 4
Reassessment
Evaluate response after 3-4 months of stable dosing 2. If inadequate response (persistent frequent/severe attacks affecting quality of life), consider: